STOCK TITAN

Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, from 1:30 to 2:10 p.m. EST. This event can be accessed via a live webcast on Liquidia's website, with a recorded version available for 90 days post-event. Liquidia focuses on pulmonary hypertension treatments and utilizes its PRINT® Technology for developing innovative products like LIQ861 and LIQ865.

Positive
  • None.
Negative
  • None.

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the 20th Annual Needham Virtual Healthcare Conference.

The presentation will take place on Wednesday, April 14, 2021, from 1:30 to 2:10 p.m. Eastern Standard Time and can be accessed via a live webcast on the Liquidia website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation can be accessed for 90 days following the event.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH, and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as Treprostinil Injection. Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information
Investors & Media:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com


FAQ

What is the date of Liquidia's presentation at the Needham Virtual Healthcare Conference?

Liquidia's presentation is scheduled for April 14, 2021.

How can I access Liquidia's presentation at the conference?

The presentation can be accessed via a live webcast on Liquidia's website.

Who will present at the 20th Annual Needham Virtual Healthcare Conference?

CEO Damian deGoa will provide an overview during the presentation.

What products is Liquidia Corporation developing?

Liquidia is developing LIQ861 for pulmonary hypertension and LIQ865 for post-operative pain management.

How long will the recorded version of Liquidia's presentation be available?

The recorded version will be available for 90 days following the event.

Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

LQDA Latest News

LQDA Stock Data

901.38M
60.47M
19.49%
54.31%
12.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MORRISVILLE